Andrew Blauvelt

"Due to the impressive results thus far, up to 13 additional patients may be enrolled into this study," said Andrew Blauvelt, M.D., Principal Investigator of the study at the Dermatology Branch of the National Cancer Institute in Bethesda, Maryland."During this phase, patients with severe psoriasis will receive intravenous infusions once every 2 weeks in hope of inducing even greater improvements."

As with the initial study, no other therapies for psoriasis will be given to patients during treatment, and all patients must have had previous systemic treatment (e.g., methotrexate, cyclosporine, etc.) to control their disease.The study's primary efficacy measure will be the Psoriasis Area Severity Index (PASI).

Psoriasis is a chronic, hyperproliferative, inflammatory disease of the skin that affects up to 3% of the world's population.

"Due to the impressive results thus far, up to 13 additional patients may be enrolled into this study," said Andrew Blauvelt, M.D., Principal Investigator of the study at the Dermatology Branch of the National Cancer Institute in Bethesda, Maryland."During this phase, patients with severe psoriasis will receive intravenous infusions once every 2 weeks in hope of inducing even greater improvements."

As with the initial study, no other therapies for psoriasis will be given to patients during treatment, and all patients must have had previous systemic treatment (e.g., methotrexate, cyclosporine, etc.) to control their disease.The study's primary efficacy measure will be the Psoriasis Area Severity Index (PASI).

Psoriasis is a chronic, hyperproliferative, inflammatory disease of the skin that affects up to 3% of the world's population.

"Due to the impressive results thus far, up to 13 additional patients may be enrolled into this study," said Andrew Blauvelt, M.D., Principal Investigator of the study at the Dermatology Branch of the National Cancer Institute in Bethesda, Maryland."During this phase, patients with severe psoriasis will receive intravenous infusions once every 2 weeks in hope of inducing even greater improvements."

As with the initial study, no other therapies for psoriasis will be given to patients during treatment, and all patients must have had previous systemic treatment (e.g., methotrexate, cyclosporine, etc.) to control their disease.The study's primary efficacy measure will be the Psoriasis Area Severity Index (PASI).

Psoriasis is a chronic, hyperproliferative, inflammatory disease of the skin that affects up to 3% of the world's population.